5,5-dihydroxy-L-norvaline L-peptide linking ATOMP C5 H11 N O4 GLU 0 2011-02-09 2011-07-13 N REL 149.145 E GLJ N Corina N 1QR3 RCSB N N 0 1 N N N -8.297 21.805 36.085 1.137 1.758 0.466 N GLJ 1 CA C 0 1 N N S -7.323 21.678 35.002 1.179 0.295 0.598 CA GLJ 2 C C 0 1 N N N -7.966 21.066 33.697 2.439 -0.231 -0.038 C GLJ 3 O O 0 1 N N N -9.165 21.229 33.420 3.034 0.442 -0.847 O GLJ 4 CB C 0 1 N N N -6.099 20.893 35.510 -0.038 -0.315 -0.100 CB GLJ 5 CG C 0 1 N N N -5.157 20.738 34.324 -1.313 0.121 0.625 CG GLJ 6 CD C 0 1 N N N -5.773 19.884 33.230 -2.530 -0.490 -0.073 CD GLJ 7 OE O 0 1 N N N -6.113 18.608 33.741 -2.642 0.049 -1.393 OE1 GLJ 8 H H 0 1 N N N -7.851 22.195 36.891 1.149 2.033 -0.505 H GLJ 9 HA H 0 1 N N N -6.979 22.678 34.701 1.165 0.026 1.654 HA GLJ 10 HB2 H 0 1 N N N -5.603 21.441 36.325 -0.073 0.027 -1.134 HB2 GLJ 11 HB3 H 0 1 N N N -6.406 19.907 35.888 0.038 -1.402 -0.079 HB3 GLJ 12 HG2 H 0 1 N N N -4.937 21.735 33.914 -1.278 -0.221 1.659 HG2 GLJ 13 HG3 H 0 1 N N N -4.230 20.257 34.669 -1.390 1.208 0.604 HG3 GLJ 14 HD2 H 0 1 N N N -6.683 20.378 32.858 -2.411 -1.571 -0.131 HD2 GLJ 15 OE2 O 0 1 N Y N -4.831 19.729 32.166 -3.711 -0.179 0.669 OE2 GLJ 16 HE H 0 1 N N N -6.497 18.082 33.050 -2.751 1.009 -1.418 HE1 GLJ 17 H2 H 0 1 N Y N -9.043 22.404 35.794 0.334 2.141 0.941 H2 GLJ 18 OXT O 0 1 N Y N -7.399 20.276 32.649 2.901 -1.447 0.293 OXT GLJ 19 HE2 H 0 1 N Y N -5.213 19.195 31.479 -4.523 -0.535 0.284 HE2 GLJ 20 HXT H 0 1 N Y N -8.069 20.073 32.007 3.713 -1.741 -0.142 HXT GLJ 21 sing N N 1 sing N N 2 sing N N 3 sing N N 4 sing N N 5 doub N N 6 sing N N 7 sing N N 8 sing N N 9 sing N N 10 sing N N 11 sing N N 12 sing N N 13 sing N N 14 sing N N 15 sing N N 16 sing N N 17 sing N N 18 sing N N 19 sing N N 20 O=C(O)C(N)CCC(O)O N[C@@H](CCC(O)O)C(O)=O N[CH](CCC(O)O)C(O)=O C(CC(O)O)[C@@H](C(=O)O)N C(CC(O)O)C(C(=O)O)N InChI=1S/C5H11NO4/c6-3(5(9)10)1-2-4(7)8/h3-4,7-8H,1-2,6H2,(H,9,10)/t3-/m0/s1 FIKXYBCGRJPSSD-VKHMYHEASA-N 5,5-dihydroxy-L-norvaline (2S)-2-azanyl-5,5-dihydroxy-pentanoic acid RCSB RCSB